The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials.

Rohani P, Malekpour Alamdari N, Bagheri SE, Hekmatdoost A, Sohouli MH

Frontiers in endocrinology9 Aug 2023Cited by 8 (Europe PMC)

PMID37621649PMCIDPMC10446893DOI10.3389/fendo.2023.1230206PepBankPUB-37621649

Summary

BackgroundDespite the fact that obesity and overweight are serious major health problems worldwide, fighting against them is also considered a challenging issue. Several interventional studies have evaluated the potential weight-reduction effect of Tirzepatide. In order to obtain a better viewpoint from them, this study aimed to comprehensively investigate the effects of subcutaneous Tirzepatide on obesity and overweight.MethodsScopus, PubMed/Medline, Web of Science, Cochrane, and Embase databases were searched using standard keywords to identify all controlled trials investigating the weight loss effects of Tirzepatide. Pooled weighted mean difference and 95% confidence intervals were achieved by random-effects model analysis for the best estimation of outcomes. The statistical heterogeneity and publication bias were determined using the Cochran's Q test and I² statistics and using the funnel plot and Egger's test, respectively.ResultsTwenty three treatments arm with 7062 participants' were included in this systematic review and meta-regression analysis. The pooled findings showed that Tirzepatide vs placebo significantly reduced body weight (weighted mean difference (WMD): -11.34 kg, 95% confidence interval (CI): -12.79 to -9.88, P< 0.001), body mass index (BMI) (WMD: -3.11 kg/m2, 95% CI: -4.36 to -1.86, P< 0.001), and waist circumference (WC) (WMD: -7.24 cm, 95% CI -10.12 to -4.36, P< 0.001). These reductions were even greater, especially with higher doses and duration of Tirzepatide.ConclusionsTirzepatide medication had significant effects on weight management with the reduction of body weight, BMI, and WC. Administration of Tirzepatide can be considered a therapeutic strategy for overweight or obese people.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-regression of trials in people with overweight or obesity, subcutaneous tirzepatide reduced body weight versus placebo.
In plain wordsIn people with overweight or obesity, tirzepatide injections reduced body weight more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody weight (weighted mean difference)
Study
n = 7,062
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
WMD
−11.34 kg
body weight
Source sentences
Summary
The pooled findings showed that Tirzepatide vs placebo significantly reduced body weight (weighted mean difference (WMD): -11.34 kg, 95% confidence interval (CI): -12.79 to -9.88, P< 0.001), body mass index (BMI) (WMD: -3.11 kg/m2, 95% CI: -4.36 to -1.86, P< 0.001), and waist circumference (WC) (WMD: -7.24 cm, 95% CI -10.12 to -4.36, P< 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty three treatments arm with 7062 participants' were included in this systematic review and meta-regression analysis.
Show in the study text Report a problemFND-3762164901
02HumanSystematic reviewEfficacy outcome
In a meta-regression of trials in people with overweight or obesity, subcutaneous tirzepatide reduced body mass index versus placebo.
In plain wordsIn people with overweight or obesity, tirzepatide injections lowered body mass index more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseBody mass index (weighted mean difference)
Study
n = 7,062
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
WMD
−3.11 kg/m2
BMI
Source sentences
Summary
The pooled findings showed that Tirzepatide vs placebo significantly reduced body weight (weighted mean difference (WMD): -11.34 kg, 95% confidence interval (CI): -12.79 to -9.88, P< 0.001), body mass index (BMI) (WMD: -3.11 kg/m2, 95% CI: -4.36 to -1.86, P< 0.001), and waist circumference (WC) (WMD: -7.24 cm, 95% CI -10.12 to -4.36, P< 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty three treatments arm with 7062 participants' were included in this systematic review and meta-regression analysis.
Show in the study text Report a problemFND-3762164902
03HumanSystematic reviewEfficacy outcome
In a meta-regression of trials in people with overweight or obesity, subcutaneous tirzepatide reduced waist circumference versus placebo.
In plain wordsIn people with overweight or obesity, tirzepatide injections reduced waist size more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference (weighted mean difference)
Study
n = 7,062
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Measurements
WMD
−7.24 cm
waist circumference
Source sentences
Summary
The pooled findings showed that Tirzepatide vs placebo significantly reduced body weight (weighted mean difference (WMD): -11.34 kg, 95% confidence interval (CI): -12.79 to -9.88, P< 0.001), body mass index (BMI) (WMD: -3.11 kg/m2, 95% CI: -4.36 to -1.86, P< 0.001), and waist circumference (WC) (WMD: -7.24 cm, 95% CI -10.12 to -4.36, P< 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty three treatments arm with 7062 participants' were included in this systematic review and meta-regression analysis.
Show in the study text Report a problemFND-3762164903
04HumanSystematic reviewEfficacy outcome
In a meta-regression of trials in people with overweight or obesity, the reductions were greater with higher doses and longer duration of tirzepatide.
In plain wordsIn people with overweight or obesity, tirzepatide reduced weight more with higher doses and longer treatment.
Peptide
Tirzepatide
Outcome
DecreaseWeight reduction by dose and duration
Study
n = 7,062
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
These reductions were even greater, especially with higher doses and duration of Tirzepatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty three treatments arm with 7062 participants' were included in this systematic review and meta-regression analysis.
Show in the study text Report a problemFND-3762164904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.